임상 레이더 AI | ||
|---|---|---|
임상시험 NCT06016855은(는) 소화기계 신경내분비 종양 G1, Digestive System Neuroendocrine Tumor G2, 전이성 소화기계 신경내분비 종양, 간에 전이된 악성 신생물, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '시험 설명하기'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT06016855은(는) 치료을(를) 알아보기 위한 연구입니다. 이 연구는 소화기계 신경내분비 종양 G1, Digestive System Neuroendocrine Tumor G2, 전이성 소화기계 신경내분비 종양, 간에 전이된 악성 신생물, Pancreatic Neuroendocrine Tumor G1, Pancreatic Neuroendocrine Tumor G2에 대해 진행되며, 4상 중재연구으로 현재 상태는 모집중입니다. 연구는 2024년 5월 31일에 시작되어 6명의 참여자를 모집하고 있습니다. Vanderbilt-Ingram Cancer Center이(가) 진행하며, 2028년 5월 28일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2024년 7월 3일에 갱신되었습니다.
간단한 개요
This phase IV trial evaluates how well giving standard of care (SOC) peptide receptor radionuclide therapy (PRRT) after SOC surgical removal of as much tumor as possible (debulking surgery) works in treating patients with grade 1 or 2, somatostatin receptor (SSTR) positive, gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that have spread from where they first started (primary site) to the liver (hepatic metastasis). Lutetium Lu 177 dotatate is a radioactive drug that uses targeted radiation to kill tumor cells. Lutetium Lu 177 dotatate includes a radioactive form (an isotope) of the element called lutetium. This radioactive isotope (Lu-177) is attached to a molecule called dotatate. On the surface of GEP-NET tumor cells, a receptor called a somatostatin receptor binds to dotatate. When this binding occurs, the lutetium Lu 177 dotatate drug then enters somatostatin receptor-positive tumor cells, and radiation emitted by Lu-177 helps kill the cells. Giving lutetium Lu 177 dotatate after surgical debulking may better treat patients with grade 1/2 GEP-NETs
상세한 설명
PRIMARY OBJECTIVES:
I. To measure objective response rate of a combination standard of care treatment in gastroenteropancreatic neuroendocrine tumors by initiating lutetium Lu 177 dotatate within 90 days of surgical debulking.
II. To assess the radiomic profile including somatostatin receptor standardized uptake values (SSTR SUV) of large and non-large tumors in study patients)
III: To assess the safety and tolerability of peptide receptor radionuclide therapy (PRRT) post-surgical debulking in patients on study.
IV. To assess the tumor genomic profile of large, resected tumors from patients and assess for signatures of radioresistance.
OUTLINE:
Patients undergo surgical debulking on day 0 and receive lutetium Lu 177 dotatate (177Lu dotatate) intravenously (IV) over 30 to 40 minutes on day 1 of each cycle. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan or magnetic resonance imaging (MRI) throughout the trial, and undergo copper Cu 64 dotatate positron emission tomography/CT (dotatate PET/CT) during screening and on study.
After completion of study treatment, patients are followed up at 30-37 days after last dose and then every 3 months for 2 years.
공식 제목
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
질환/상태
소화기계 신경내분비 종양 G1Digestive System Neuroendocrine Tumor G2전이성 소화기계 신경내분비 종양간에 전이된 악성 신생물Pancreatic Neuroendocrine Tumor G1Pancreatic Neuroendocrine Tumor G2출판물
이 임상 시험에 대해 발표된 과학 논문 및 연구 자료.기타 연구 식별자
NCT 번호
실제 연구 시작일
2024-05-31
최신 업데이트 게시
2024-07-03
예상 연구 완료일
2028-05-28
계획된 등록 인원
6
연구종류
중재연구
단계/상
4상
상태
모집중
주요 목적
치료
설계 할당
해당 없음
중재 모델
단일군설계
맹검 (마스킹)
없음 (공개라벨)
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
실험적Treatment (surgical debulking, 177Lu dotatate) Patients undergo surgical debulking on day 0 and receive 177Lu dotatate IV over 30 to 40 minutes on day 1 of each cycle. Treatment repeats every 56 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan or MRI throughout the trial, and undergo dotatate PET/CT during screening and on study. | Tumor Debulking Undergo surgical debulking Lutetium Lu 177 Dotatate Given by IV 컴퓨터 단층 촬영 Undergo Computed Tomography 자기 공명 영상 Undergo Magnetic Resonance Imaging Copper Cu 64 Dotatate Given by IV 양전자 방출 단층촬영 Undergo Positron Emission Tomography |
주요결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Somatostatin receptor standardized uptake values (SSTR SUV) | SSTR SUV (not limited to but including measures such as SSTR SUV max, SSTR SUV mean) will be estimated for the patients undergoing post-operative research dotatate scans and compared to values from peptide receptor radionuclide therapy (PRRT) eligibility-conferring dotatate scans in these same patients. These quantitative analytics will be performed by central review. Changes in SSTR SUV values will be analyzed with summary statistics. | Up to 2 years |
Progression-free survival | Will be estimated by the Kaplan-Meier method. | From the start of PRRT to the date the patient progresses radiographically or succumbs to the disease, assessed up to 2 years |
Overall response rate | Will be estimated by measuring the number of patients who achieve a complete response or partial response by Response Evaluation Criteria in Solid Tumors (RECIST 1.1) criteria on restaging computed tomography or magnetic resonance imaging scans =\< 6 months from PRRT completion, from the total number of patients who received the study treatment and possessed measurable disease post-surgical debulking. The number of patients who possessed measurable disease which did not meet RECIST 1.1 eligibility criteria post-surgical debulking will also be recorded. | Up to 2 years |
Overall survival | Will be estimated by the Kaplan-Meier method. | From the start of PRRT to the date the patient progresses radiographically or succumbs to the disease, assessed up to 2 years |
Incidence of adverse events | Toxicity will be estimated by documenting the grade 3/4 adverse events, according to Common Terminology Criteria for Adverse Events version 5.0, experienced by study patients. | Up to 2 years |
Gene mutations | Mutations in genes associated with radioresistance (defined from other malignancies) and other mutations in large resected neuroendocrine tumors will be recorded. Mutations will be described descriptively. | Up to 2 years |
적격성 기준
연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
- Signed and dated written informed consent
- Male or female >= 18 years of age on the day of signing informed consent
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
- Histologically confirmed well-differentiated gastrointestinal or pancreatic neuroendocrine tumor that is grade 1 or grade 2 (Ki-67 =< 20%)
- Somatostatin receptor avidity of known or suspected neuroendocrine tumor (NET) lesion(s) assessed by a baseline copper-64 dotatate PET/CT scan performed within 6 months (180 days) prior to surgical debulking on study day 0. The somatostatin receptor avidity of the majority of suspected NET lesion(s) must be >= normal liver uptake
- Patient must have hepatic metastasis or hepatic metastases. Provided required hepatic metastatic disease is present, patient can also have any other site or sites of metastatic disease
- White blood cell count (WBC) >= 2000/uL (resulted =< 90 days prior to surgical debulking on day 0 of participation in this study)
- Platelets >= 75,000/uL (resulted =< 90 days prior to surgical debulking on day 0 of participation in this study)
- Hemoglobin >= 8.0 g/dL (resulted =< 90 days prior to surgical debulking on day 0 of participation in this study)
- Creatinine clearance (CrCl) >= 30 mL/minute (as calculated by the Cockcroft-Gault Formula with estimated creatinine clearance rate [eCCR] >= 30 mL/min required for eligibility inclusion; or calculated/measured by an alternative established institutional standard consistently applied across participants at the site) (resulted =< 90 days prior to surgical debulking on day 0 of participation in this study)
- Total bilirubin =< 3.0 times institutional upper limit of normal (ULN) (resulted =< 90 days prior to surgical debulking on day 0 of participation in this study)
- Serum albumin >= 3.0 g/dL unless the prothrombin time is within normal range (resulted =< 90 days prior to surgical debulking on day 0 of participation in this study)
- Women must not be breastfeeding and further agree to not breastfeed during treatment with lutetium Lu 177 dotatate; and for at least 2.5 months after patient's final dose of lutetium Lu 177 dotatate
- A woman of childbearing potential (WOCBP) - must have a negative serum or urine pregnancy test resulted within 28 days prior to initiation of first dose of lutetium Lu 177 dotatate on cycle 1, day 1; and must agree to follow instructions for using acceptable contraception from the time of signing consent, and until 7 months after her final dose of lutetium Lu 177 dotatate
- A man able to father children who is sexually active with a WOCBP must agree to follow instructions for using acceptable contraception, from the time of signing consent, and until 4 months after his final dose of lutetium Lu 177 dotatate
- Patient has any tumor > 3 cm deemed to be inoperable
- Patient has disease which is considered to be completely surgically resectable
- Patient has grade 3 neuroendocrine neoplasm (well-differentiated or poorly-differentiated tumor)
- Prior receipt of peptide receptor radionuclide therapy (PRRT)
- Patient possesses untreated or growing brain metastases (growth within 90 days prior to surgical debulking on day 0 of participation in this study)
- Unstable angina, congestive heart failure with New York Heart Association (NYHA) functional classification III or IV, or uncontrolled symptomatic cardiac arrythmia
- Any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which in the judgment of the patient's study physician may reasonably be expected to interfere with patient's completion of the study
Vanderbilt-Ingram Cancer Center연구 책임자
Kamran Idrees, 책임연구자, Associate Professor of Surgery, Vanderbilt-Ingram Cancer Center
연구 대표 연락처
연락처: Vanderbilt-Ingram Services for Timely Access, 800-811-8480, [email protected]
1 1개국에 임상시험 장소
Tennessee
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37203, United States
Vanderbilt-Ingram Service for Timely Access, 연락처, 800-811-8480, [email protected]
Kamran Idrees, MD, 책임연구자
모집중